Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Müller-Wieland

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Deutsche Medizinische Wochenschrift (1946)|February 23, 2018
[Type 2 Diabetes Diabetes in Older Adults: Example for Patient-Centered Drug Therapy]Dirk Müller-Wieland
MMW Fortschritte Der Medizin|May 28, 2015
[Modern management with oral antihyperglycemic agents in type 2 diabetes]Dirk Müller-Wieland
Medizinische Monatsschrift Fur Pharmazeuten|March 18, 2016
[Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment]Dirk Müller-Wieland
MMW Fortschritte Der Medizin|July 3, 2016
[Not Available]Dirk Müller-Wieland
Expert Opinion on Therapeutic Targets|April 23, 2004
Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance?Jorg Kotzka, Dirk Müller-Wieland
Current Atherosclerosis Reports|January 8, 2025
Debate: Lipid-lowering Therapies and Diabetes DevelopmentJulia Brandts, Dirk Müller-Wieland
Medizinische Klinik (Munich, Germany : 1983)|December 20, 2003
[Hyperlipidemia: therapeutic principles in clinical practice]Dirk Müller-Wieland, Wilhelm Krone
Frontiers in Endocrinology|September 5, 2022
Editorial: Adipose tissue dysfunctionMatthias Blüher, Dirk Müller-Wieland
Deutsche Medizinische Wochenschrift (1946)|April 30, 2020
[Therapy of type 2 diabetes - Recommendations of the European Association for the Study of Diabetes (EASD)]Dirk Müller-Wieland, Nikolaus Marx
Current Atherosclerosis Reports|July 28, 2019
PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular RiskJulia Brandts, Dirk Müller-Wieland
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Deutsche Medizinische Wochenschrift (1946)|February 23, 2018
[Type 2 Diabetes Diabetes in Older Adults: Example for Patient-Centered Drug Therapy]Dirk Müller-Wieland
MMW Fortschritte Der Medizin|May 28, 2015
[Modern management with oral antihyperglycemic agents in type 2 diabetes]Dirk Müller-Wieland
Medizinische Monatsschrift Fur Pharmazeuten|March 18, 2016
[Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment]Dirk Müller-Wieland
MMW Fortschritte Der Medizin|July 3, 2016
[Not Available]Dirk Müller-Wieland
Expert Opinion on Therapeutic Targets|April 23, 2004
Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance?Jorg Kotzka, Dirk Müller-Wieland
Current Atherosclerosis Reports|January 8, 2025
Debate: Lipid-lowering Therapies and Diabetes DevelopmentJulia Brandts, Dirk Müller-Wieland
Medizinische Klinik (Munich, Germany : 1983)|December 20, 2003
[Hyperlipidemia: therapeutic principles in clinical practice]Dirk Müller-Wieland, Wilhelm Krone
Frontiers in Endocrinology|September 5, 2022
Editorial: Adipose tissue dysfunctionMatthias Blüher, Dirk Müller-Wieland
Deutsche Medizinische Wochenschrift (1946)|April 30, 2020
[Therapy of type 2 diabetes - Recommendations of the European Association for the Study of Diabetes (EASD)]Dirk Müller-Wieland, Nikolaus Marx
Current Atherosclerosis Reports|July 28, 2019
PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular RiskJulia Brandts, Dirk Müller-Wieland
Pageof 15